T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Enfu Hui,Jeanne Cheung,Jing Zhu,Xiaolei Su,Marcus J. Taylor,Heidi A. Wallweber,Dibyendu K. Sasmal,Jun Huang,Jeong M. Kim,Ira Mellman,Ronald D. Vale

DOI: https://doi.org/10.1126/science.aaf1292

IF: 56.9

2017-03-31

Science

Abstract:Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.

multidisciplinary sciences

What problem does this paper attempt to address?

CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells

Yo-Ping Lai,Lu-Cheng Kuo,Been-Ren Lin,Hung-Ju Lin,Chih-Yu Lin,Yi-Ting Chen,Pei-Wen Hsiao,Huan-Tsung Chang,Patrick Chow-In Ko,Hsiao-Chin Chen,Hsiang-Yu Chang,Jean Lu,Hong-Nerng Ho,Betty A. Wu-Hsieh,John T. Kung,Shu-Ching Chen

DOI: https://doi.org/10.1038/s42003-021-02119-9

IF: 6.548

2021-05-19

Communications Biology

Abstract:Abstract CD28 is required for T cell activation as well as the generation of CD4 + Foxp3 + Treg. It is unclear, however, how CD28 costimulation affects the development of CD8 + T cell suppressive function. Here, by use of Hepa1.6.gp33 in vitro killing assay and B16.gp33 tumor mouse model we demonstrate that CD28 engagement during TCR ligation prevents CD8 + T cells from becoming suppressive. Interestingly, our results showed that ectonucleotidase CD73 expression on CD8 + T cells is upregulated in the absence of CD28 costimulation. In both murine and human tumor-bearing hosts, CD73 is upregulated on CD28 − CD8 + T cells that infiltrate the solid tumor. UPLC-MS/MS analysis revealed that CD8 + T cells activation without CD28 costimulation produces elevated levels of adenosine and that CD73 mediates its production. Adenosine receptor antagonists block CD73-mediated suppression. Our data support the notion that CD28 costimulation inhibits CD73 upregulation and thereby prevents CD8 + T cells from becoming suppressive. This study uncovers a previously unidentified role for CD28 costimulation in CD8 + T cell activation and suggests that the CD28 costimulatory pathway can be a potential target for cancer immunotherapy.

biology
[CD28 costimulation and checkpoint inhibition in T cells]

N Beyersdorf,T Kerkau

DOI: https://doi.org/10.1007/s00108-020-00813-0

Abstract:Background: The induction of protective T cell responses requires two signals: Signal 1 is generated by activation of the T cell receptor (TCR) and signal 2 results from ligation of the CD28 molecule. Costimulation of the TCR and CD28 is necessary, as the TCR is very good at discriminating between endogenous and foreign structures (antigens), but not all foreign antigens (such as food antigens) are dangerous to the body. A strong CD28 signal, thus, indicates to the T cell that there is indeed a threat and that an immune response is urgently required. However, to avoid autoimmunity and excessive immune responses, further regulatory circuits, provided by immune checkpoints, are necessary. Objectives: To provide an introduction to immunoregulation mediated by checkpoint molecules. Materials and methods: Review of basic science papers and reports on clinical studies. Results: The most prominent and best characterized checkpoint molecules, cytotoxic T lymphocyte-associated protein‑4 (CTLA-4) and programmed cell death‑1 (PD-1), both physiologically dampen CD28-mediated costimulation. Pathologically, malignancies exploit the immunoregulatory function of checkpoint molecules by, for example, expressing ligands for PD‑1 on the cell surface, thus, avoiding being attacked by T cells. Our understanding of these negative feedback regulations has led to the development of checkpoint inhibitors, which have already become part of routine clinical care of cancer patients. Conclusions: Due to the clinical success of checkpoint inhibitors, the concept of cancer immunotherapy has received a massive boost and hopes are high that many more clinical advancements in cancer therapy can be achieved with novel forms of immunotherapy.
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

Soyoung A. Oh,Dai-Chen Wu,Jeanne Cheung,Armando Navarro,Huizhong Xiong,Rafael Cubas,Klara Totpal,Henry Chiu,Yan Wu,Laetitia Comps-Agrar,Andrew M. Leader,Miriam Merad,Merone Roose-Germa,Soren Warming,Minhong Yan,Jeong M. Kim,Sascha Rutz,Ira Mellman

DOI: https://doi.org/10.1038/s43018-020-0075-x

IF: 22.7

2020-06-22

Nature Cancer

Abstract:Inhibiting the programmed death-1 (PD-1) pathway is one of the most effective approaches to cancer immunotherapy, but its mechanistic basis remains incompletely understood. Binding of PD-1 to its ligand PD-L1 suppresses T-cell function in part by inhibiting CD28 signaling. Tumor cells and infiltrating myeloid cells can express PD-L1, with myeloid cells being of particular interest as they also express B7-1, a ligand for CD28 and PD-L1. Here we demonstrate that dendritic cells (DCs) represent a critical source of PD-L1, despite being vastly outnumbered by PD-L1+ macrophages. Deletion of PD-L1 in DCs, but not macrophages, greatly restricted tumor growth and led to enhanced antitumor CD8+ T-cell responses. Our data identify a unique role for DCs in the PD-L1–PD-1 regulatory axis and have implications for understanding the therapeutic mechanism of checkpoint blockade, which has long been assumed to reflect the reversal of T-cell exhaustion induced by PD-L1+ tumor cells.
CD28 Costimulation: From Mechanism to Therapy

Jonathan H Esensten,Ynes A Helou,Gaurav Chopra,Arthur Weiss,Jeffrey A Bluestone

DOI: https://doi.org/10.1016/j.immuni.2016.04.020

IF: 32.4

2016-05-17

Immunity

Abstract:Ligation of the CD28 receptor on T cells provides a critical second signal alongside T cell receptor (TCR) ligation for naive T cell activation. Here, we discuss the expression, structure, and biochemistry of CD28 and its ligands. CD28 signals play a key role in many T cell processes, including cytoskeletal remodeling, production of cytokines, survival, and differentiation. CD28 ligation leads to unique epigenetic, transcriptional, and post-translational changes in T cells that cannot be recapitulated by TCR ligation alone. We discuss the function of CD28 and its ligands in both effector and regulatory T cells. CD28 is critical for regulatory T cell survival and the maintenance of immune homeostasis. We outline the roles that CD28 and its family members play in human disease and we review the clinical efficacy of drugs that block CD28 ligands. Despite the centrality of CD28 and its family members and ligands to immune function, many aspects of CD28 biology remain unclear. Translation of a basic understanding of CD28 function into immunomodulatory therapeutics has been uneven, with both successes and failures. Such real-world results might stem from multiple factors, including complex receptor-ligand interactions among CD28 family members, differences between the mouse and human CD28 families, and cell-type specific roles of CD28 family members.
CD28 co-stimulation: novel insights and applications in cancer immunotherapy

Michael T. Lotze,Scott H. Olejniczak,Dimitris Skokos

DOI: https://doi.org/10.1038/s41577-024-01061-1

IF: 108.555

2024-07-26

Nature Reviews Immunology

Abstract:Substantial progress in understanding T cell signalling, particularly with respect to T cell co-receptors such as the co-stimulatory receptor CD28, has been made in recent years. This knowledge has been instrumental in the development of innovative immunotherapies for patients with cancer, including immune checkpoint blockade antibodies, adoptive cell therapies, tumour-targeted immunostimulatory antibodies, and immunostimulatory small-molecule drugs that regulate T cell activation. Following the failed clinical trial of a CD28 superagonist antibody in 2006, targeted CD28 agonism has re-emerged as a technologically viable and clinically promising strategy for cancer immunotherapy. In this Review, we explore recent insights into the molecular functions and regulation of CD28. We describe how CD28 is central to the success of current cancer immunotherapies and examine how new questions arising from studies of CD28 as a clinical target have enhanced our understanding of its biological role and may guide the development of future therapeutic strategies in oncology.

immunology
PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition

Kaitao Li,Zhou Yuan,Jintian Lyu,Eunseon Ahn,Simon J. Davis,Rafi Ahmed,Cheng Zhu

DOI: https://doi.org/10.1038/s41467-021-22965-9

IF: 16.6

2021-05-12

Nature Communications

Abstract:Abstract Despite the clinical success of blocking its interactions, how PD-1 inhibits T-cell activation is incompletely understood, as exemplified by its potency far exceeding what might be predicted from its affinity for PD-1 ligand-1 (PD-L1). This may be partially attributed to PD-1’s targeting the proximal signaling of the T-cell receptor (TCR) and co-stimulatory receptor CD28 via activating Src homology region 2 domain-containing phosphatases (SHPs). Here, we report PD-1 signaling regulates the initial TCR antigen recognition manifested in a smaller spreading area, fewer molecular bonds formed, and shorter bond lifetime of T cell interaction with peptide-major histocompatibility complex (pMHC) in the presence than absence of PD-L1 in a manner dependent on SHPs and Leukocyte C-terminal Src kinase. Our results identify a PD-1 inhibitory mechanism that disrupts the cooperative TCR–pMHC–CD8 trimolecular interaction, which prevents CD8 from augmenting antigen recognition, explaining PD-1’s potent inhibitory function and its value as a target for clinical intervention.

multidisciplinary sciences
PD-1 Expression By Dendritic Cells Is a Key Regulator of T-Cell Immunity in Cancer

Rushil Shah,Konstantinos Aliazis,Anthos Christofides,Angelique A Pham,Rinku Pal,Vassiliki A Boussiotis

DOI: https://doi.org/10.1182/blood-2023-178180

IF: 20.3

2023-11-28

Blood

Abstract:Programmed cell death 1 (PD-1) is an inhibitory receptor expressed on a variety of immune cells and a therapeutic target of checkpoint immunotherapy for cancer patients. PD-1 engagement by PD-L1 or PD-L2 can inhibit activation and expansion of tumor antigen-specific T cells. PD-1 expression in tumor-associated macrophages (TAM) correlates with impaired phagocytosis and antigen presenting function and enhanced immunosuppression. PD-1 is also expressed in dendritic cells (DC) and has been shown to correlate negatively with the outcome of DC-based cancer vaccines. On DC, PD-1 can interact with PD-L1 in cis when both of these receptors are expressed on the same cell surface. DCs are the major antigen presenting cells for cross-presenting tumor antigens to T cells, and PD-L1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor responses. Very little is known about the specific role of PD-1 on DCs function. In the present study, we sought to understand the role of PD-1 on DCs in the context of cancer. We generated mice with conditional targeting of the Pdcd1 gene (encoding for PD-1) and crossed them with CD11cCre ( Pdcd1 f/fCD11cCre) or Clec9Cre ( Pdcd1 f/fClec9Cre) resulting in specific deletion of PD-1 in DC cells. We used the MC17 fibrosarcoma syngeneic mouse model to investigate the tentative implications of DC-specific PD-1 ablation on anti-tumor responses. We found larger tumor sizes and weights in tumor-bearing Pdcd1 f/fCD11cCre mice compared to their Pdcd1 wt/wtCD11cCre control counterparts. Pdcd1 f/fCD11cCre tumor-bearing mice had significantly higher fractions of DCs in spleens and tumor-draining lymph nodes (tdLNs) but only minimal differences in their activation state and checkpoint marker expression. Similarly, CD4 + and CD8 + T cells from spleens and tdLNs were comparable in percentages and activation states. However, characterization of the immune cells at the tumor site, indicated that Pdcd1 f/fCD11cCre tumor-bearing mice had a more immunosuppressive tumor microenvironment with increased fractions of CD11b +Ly6C hiLy6G -monocytic myeloid derived suppressor cells (M-MDSCs) compared to control tumor-bearing mice. Moreover, flow cytometric analysis revealed that intratumoral M-MDSC in Pdcd1 f/fCD11cCre mice displayed enhanced expression of PD-L1 and CD38, consistent with a more activated and more immunosuppressive phenotype. Characterization of tumor infiltrating CD4 + and CD8 + T cells also revealed vast differences in composition and activation states. Specifically, Pdcd1 f/fCD11cCre mice had larger populations of intratumoral CD3 + T cells, with a greater CD4/CD8 T cell ratio, and higher percentages of CD4 + T regulatory cells. Conversely, intratumoral CD8 + T cells were reduced, and were characterized by diminished expansion of CD8 + T effector cells, and a less activated phenotype as determined by lower expression of CD25, CD69, and GITR. In syngeneic tumor experiments with B16 melanoma expressing ovalbumin (B16-Ova), Pdcd1 f/fCD11cCre mice and Pdcd1 f/fClec9Cre mice similarly had greater tumor sizes and weights compared to their control counterparts. These results indicate that selective ablation of PD-1 in DCs cells confers a more immunosuppressive tumor microenvironment by promoting T regulatory cell expansion and diminishing CD8 + T effector cell activation compromising anti-tumor responses.

hematology
PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation

Daniela Chmiest,Silvia Podavini,Kalliopi Ioannidou,David Vallois,Chantal Décaillet,Montserrat Gonzalez,Manfredo Quadroni,Kevin Blackney,Rebekka Schairer,Laurence L de Leval,Margot Thome

DOI: https://doi.org/10.1182/bloodadvances.2023011901

IF: 7.642

2024-03-28

Blood Advances

Abstract:The inhibitory cell surface receptor programmed death 1 (PD1) is a major target for antibody-based cancer immunotherapies. Nevertheless, a substantial number of patients fail to respond to the treatment or experience adverse effects. An improved understanding of intracellular pathways targeted by PD1 is thus needed to develop better predictive and prognostic biomarkers. Here, via unbiased phosphoproteome analysis of primary human T cells, we demonstrate that PD1 triggering inhibited the phosphorylation and physical association with PKC theta (PKCof a variety of cytoskeleton-related proteins. PD1 blocked activation and recruitment of PKCθ to the forming immune synapse (IS) in a SHP1/SHP2 tyrosine phosphatase-dependent manner. Consequently, PD1 engagement led to impaired synaptic phosphorylation of cytoskeleton-related proteins and formation of smaller IS. TCR-induced phosphorylation of the PKCθ substrate and binding partner Vimentin was long-lasting and it could be durably inhibited by PD1 triggering. Vimentin phosphorylation in intratumoral T cells also inversely correlated with PDL1 levels in human lung carcinoma. Thus, PKCθ and its substrate Vimentin represent important targets of PD1-mediated T-cell inhibition, and low levels of Vimentin phosphorylation may serve as a biomarker for the activation of the PD1 pathway.

hematology
CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

Belinda Palermo,Ornella Franzese,Giuseppe Frisullo,Lorenzo D'Ambrosio,Mariangela Panetta,Giulia Campo,Daniel D'Andrea,Isabella Sperduti,Francesca De Nicola,Frauke Goeman,Filippo Gallina,Paolo Visca,Francesco Facciolo,Paola Nisticò

DOI: https://doi.org/10.1186/s13046-023-02846-3

2023-10-28

Abstract:Background: Immune checkpoint blockade (ICB) has significantly prolonged survival of non-small cell lung cancer (NSCLC) patients, although most patients develop mechanisms of resistance. Recently single-cell RNA-sequencing (scRNA-Seq) revealed a huge T-cell phenotypic and (dys)functional state variability. Accordingly, T-cell exhaustion is recognized as a functional adaptation, with a dynamic progression from a long-lived "pre-exhausted stem-like progenitor" to a "terminally exhausted" state. In this scenario it is crucial to understand the complex interplay between co-stimulatory and inhibitory molecules in CD8+ T-cell functionality. Methods: To gain a baseline landscape of the composition, functional states, and transcriptomic signatures predictive of prognosis, we analyzed CD8+ T-cell subsets characterized by the presence/absence of PD1 and CD28 from periphery, adjacent non-tumor tissue and tumor site of a cohort of treatment-naïve NSCLC patients, by integrated multiparametric flow cytometry, targeted multi-omic scRNA-seq analyses, and computational pipelines. Results: Despite the increased PD1 levels, an improved PD1+CD28+ T-cell polyfunctionality was observed with the transition from periphery to tumor site, associated with lack of TIGIT, TIM-3 and LAG-3, but not with Ag-experienced-marker CD11a. Differently from CD28+ T cells, the increased PD1 levels in the tumor were associated with reduced functionality in PD1+CD28- T cells. CD11ahigh, although expressed only in a small fraction of this subset, still sustained its functionality. Absence of TIGIT, TIM-3 and CTLA-4, alone or combined, was beneficial to CD28- T cells. Notably, we observed distinct TRM phenotypes in the different districts, with CD28+ T cells more capable of producing TGFβ in the periphery, potentially contributing to elevated CD103 levels. In contrast CD28- TRM mainly produced CXCL13 within the tumor. ScRNA-seq revealed 5 different clusters for each of the two subsets, with distinctive transcriptional profiles in the three districts. By interrogating the TCGA dataset of patients with lung adenocarcinoma (LUAD) and metastatic NSCLC treated with atezolizumab, we found signatures of heterogeneous TRM and "pre-exhausted" long-lived effector memory CD8+ T cells associated with improved response to ICB only in the presence of CD28. Conclusions: Our findings identify signatures able to stratify survival of LUAD patients and predict ICB response in advanced NSCLC. CD28 is advocated as a key determinant in the signatures identified, in both periphery and tumor site, thus likely providing feasible biomarkers of ICB response.
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L Banta,Xiaozheng Xu,Avantika S Chitre,Amelia Au-Yeung,Chikara Takahashi,William E O'Gorman,Thomas D Wu,Stephanie Mittman,Rafael Cubas,Laetitia Comps-Agrar,Amit Fulzele,Eric J Bennett,Jane L Grogan,Enfu Hui,Eugene Y Chiang,Ira Mellman,Karl L. Banta,Avantika S. Chitre,William E. O’Gorman,Thomas D. Wu,Eric J. Bennett,Jane L. Grogan,Eugene Y. Chiang

DOI: https://doi.org/10.1016/j.immuni.2022.02.005

IF: 32.4

2022-03-01

Immunity

Abstract:Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8+ T cells. Although PD-1 and TIGIT are thought to regulate different costimulatory receptors (CD28 and CD226), effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. CD226 expression associated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-PD-L1 antibody atezolizumab. CD226 and CD28 were co-expressed on NSCLC infiltrating CD8+ T cells poised for expansion. Mechanistically, PD-1 inhibited phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD); TIGIT's ICD was dispensable, with TIGIT restricting CD226 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of CD226 signaling, and optimal anti-tumor CD8+ T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic.

immunology
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.

Han Yao,Huanbin Wang,Chushu Li,Jing-Yuan Fang,Jie Xu

DOI: https://doi.org/10.3389/fimmu.2018.01774

IF: 7.3

2018-01-01

Frontiers in Immunology

Abstract:Programmed death 1 (PD-1) and its two natural ligands PD-L1 and PD-L2 are responsible for delivering inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. In previous studies, PD-1 was found only expressed on the surface of immune cells, such as T cells and B cells while PD-1's ligands PD-L1 and PD-L2 were found expressed in some tumor cells. However, recent studies revealed intrinsic expression of PD-1 in melanoma and some other cancers. In melanoma cells, PD-1 can be activated by its ligand PD-L1 expressed by tumor cells, modulating downstream mammalian target of rapamycin signaling and promoting tumor growth independent of adaptive immunity. In addition to melanoma, PD-1 was also detected in liver cancer cells as well as in non-small lung cancer cells. Unlike its oncogenic functions in melanoma and hepatic carcinoma cells, PD-1 seemed to play a distinct role in lung cancer, as blockade of PD-1 instead promoted tumor cells proliferation. Tumor-intrinsic PD-1 expression seems to be widespread in many tumor types, according to our reanalysis on cancer transcriptomic and proteomic data. The multifaceted roles of PD-1 in tumor cells beyond immune checkpoint signaling may explain the differential therapeutic effects of anti-PD-1 and anti-PD-L1 drugs and provide crucial information when developing combinatorial approaches to enhance antitumor immunity.
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Luoyan Ai,Antao Xu,Jie Xu

DOI: https://doi.org/10.1007/978-981-15-3266-5_3

2020-01-01

Advances in experimental medicine and biology

Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.
CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis

Sunil Acharya,Rafet Basar,May Daher,Hind Rafei,Ping Li,Nadima Uprety,Emily Ensley,Mayra Shanley,Bijender Kumar,Pinaki P. Banerjee,Luciana Melo Garcia,Paul Lin,Vakul Mohanty,Kun Hee Kim,Xianli Jiang,Yuchen Pan,Ye Li,Bin Liu,Ana Karen. Nunez Cortes,Chenyu Zhang,Mohsen Fathi,Ali Rezvan,Melisa J. Montalvo,Sophia L. Cha,Francia Reyes-Silva,Rejeena Shrestha,Xingliang Guo,Kiran Kundu,Alexander Biederstadt,Luis Muniz-Feliciano,Gary M. Deyter,Mecit Kaplan,Xin Ru Jiang,Enli Liu,Antrix Jain,Janos Roszik,Natalie W. Fowlkes,Luisa M. Solis Soto,Maria Gabriela Raso,Joseph D. Khoury,Pei Lin,Francisco Vega,Navin Varadarajan,Ken Chen,David Marin,Elizabeth J. Shpall,Katayoun Rezvani

DOI: https://doi.org/10.1158/2159-8290.cd-24-0096

IF: 28.2

2024-06-21

Cancer Discovery

Abstract:Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3Z creates a platform that recruits critical kinases, such as LCK and ZAP70, initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy.

oncology
The Role of the CD28 Family Receptors in T-Cell Immunomodulation

Klaudia Ciesielska-Figlon,Katarzyna A. Lisowska

DOI: https://doi.org/10.3390/ijms25021274

IF: 5.6

2024-01-20

International Journal of Molecular Sciences

Abstract:The CD28 family receptors include the CD28, ICOS (inducible co-stimulator), CTLA-4 (cytotoxic T-lymphocyte antigen-4), PD-1 (programmed cell death protein 1), and BTLA (B- and T-lymphocyte attenuator) molecules. They characterize a group of molecules similar to immunoglobulins that control the immune response through modulating T-cell activity. Among the family members, CD28 and ICOS act as enhancers of T-cell activity, while three others—BTLA, CTLA-4, and PD-1—function as suppressors. The receptors of the CD28 family interact with the B7 family of ligands. The cooperation between these molecules is essential for controlling the course of the adaptive response, but it also significantly impacts the development of immune-related diseases. This review introduces the reader to the molecular basis of the functioning of CD28 family receptors and their impact on T-cell activity.

biochemistry & molecular biology,chemistry, multidisciplinary
Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Muhua Chen,Lei Bie,Jieer Ying

DOI: https://doi.org/10.1016/j.biopha.2023.115514

Abstract:Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene and is constitutively expressed on the surface of immune cells. As a receptor and immune checkpoint, PD-1 can bind to programmed death ligand-1/programmed death ligand-2 (PD-L1/PD-L2) in tumor cells, leading to tumor immune evasion. Anti-PD-1 and anti-PD-L1 are important components in tumor immune therapy. PD-1 is also expressed as an intrinsic variant (iPD-1) in cancer cells where it plays important roles in malignant progression as proposed by recent studies. However, iPD-1 has received much less attention compared to PD-1 expressed on immune cells although there is an unmet medical need for fully elucidating the mechanisms of actions to achieve the best response in tumor immunotherapy. iPD-1 suppresses tumorigenesis in non-small cell lung cancer (NSCLC) and colon cancer, whereas it promotes tumorigenesis in melanoma, hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), thyroid cancer (TC), glioblastoma (GBM), and triple-negative breast cancer (TNBC). In this review, we focus on the role of iPD-1 in tumorigenesis and development and its molecular mechanisms. We also deeply discuss nivolumab-based combined therapy in common tumor therapy. iPD-1 may explain the different therapeutic effects of anti-PD-1 treatment and provide critical information for use in combined anti-tumor approaches.
Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

Annoor Awadasseid,Yongnan Zhou,Koutian Zhang,Kaiming Tian,Yanling Wu,Wen Zhang

DOI: https://doi.org/10.1016/j.biopha.2022.114057

2022-12-03

Abstract:PD-1 (Programmed cell death-1) is a receptor that inhibits the activation of T cells and is an important target for cancer immunotherapy. PD-1 expression stays high on antigen-specific T cells that have been stimulated for a long time, making them less responsive to stimuli. Consequently, there has been a recent surge in the number of researchers focusing on how the PD-1 axis delivers inhibitory signals to uncover new therapeutic targets. As an inhibitory signaling mechanism, the PD-1 axis controls immunological responses. Blocking the PD-1 axis has been shown to have long-lasting effects on various cancers, demonstrating the crucial role of PD-1 in blocking anti-tumor immunity. Despite this role, most patients do not respond to PD-1 monotherapy, and some have experienced adverse events. Many challenges remain regarding the PD-1 signaling axis to be addressed. In this review, we outline the most recent research and prospects of PD-1 signal inhibitors to enhance cervical cancer therapy.

pharmacology & pharmacy,medicine, research & experimental
PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Jinhua Liu,Zichao Chen,Yaqun Li,Wenjie Zhao,JiBiao Wu,Zhen Zhang

DOI: https://doi.org/10.3389/fphar.2021.731798

IF: 5.6

2021-09-01

Frontiers in Pharmacology

Abstract:Programmed death protein 1 (PD1) is a common immunosuppressive member on the surface of T cells and plays an imperative part in downregulating the immune system and advancing self-tolerance. Its ligand programmed cell death ligand 1 (PDL1) is overexpressed on the surface of malignant tumor cells, where it binds to PD1, inhibits the proliferation of PD1-positive cells, and participates in the immune evasion of tumors leading to treatment failure. The PD1/PDL1-based pathway is of great value in immunotherapy of cancer and has become an important immune checkpoint in recent years, so understanding the mechanism of PD1/PDL1 action is of great significance for combined immunotherapy and patient prognosis. The inhibitors of PD1/PDL1 have shown clinical efficacy in many tumors, for example, blockade of PD1 or PDL1 with specific antibodies enhances T cell responses and mediates antitumor activity. However, some patients are prone to develop drug resistance, resulting in poor treatment outcomes, which is rooted in the insensitivity of patients to targeted inhibitors. In this paper, we reviewed the mechanism and application of PD1/PDL1 checkpoint inhibitors in tumor immunotherapy. We hope that in the future, promising combination therapy regimens can be developed to allow immunotherapeutic tools to play an important role in tumor treatment. We also discuss the safety issues of immunotherapy and further reflect on the effectiveness of the treatment and the side effects it brings.

pharmacology & pharmacy
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation

Kathryn E. Beckermann,Rachel Hongo,Xiang Ye,Kirsten Young,Katie Carbonell,Diana C. Contreras Healey,Peter J. Siska,Sierra Barone,Caroline E. Roe,Christof C. Smith,Benjamin G. Vincent,Frank M. Mason,Jonathan M. Irish,W. Kimryn Rathmell,Jeffrey C. Rathmell

DOI: https://doi.org/10.1172/jci.insight.138729

IF: 9.4958

2020-08-20

JCI Insight

Abstract:Metabolic reprogramming dictates the fate and function of stimulated T cells, yet these pathways can be suppressed in T cells in tumor microenvironments. We previously showed that glycolytic and mitochondrial adaptations directly contribute to reducing the effector function of renal cell carcinoma (RCC) CD8+ tumor-infiltrating lymphocytes (TILs). Here we define the role of these metabolic pathways in the activation and effector functions of CD8+ RCC TILs. CD28 costimulation plays a key role in augmenting T cell activation and metabolism, and is antagonized by the inhibitory and checkpoint immunotherapy receptors CTLA4 and PD-1. While RCC CD8+ TILs were activated at a low level when stimulated through the T cell receptor alone, addition of CD28 costimulation greatly enhanced activation, function, and proliferation. CD28 costimulation reprogrammed RCC CD8+ TIL metabolism with increased glycolysis and mitochondrial oxidative metabolism, possibly through upregulation of GLUT3. Mitochondria also fused to a greater degree, with higher membrane potential and overall mass. These phenotypes were dependent on glucose metabolism, as the glycolytic inhibitor 2-deoxyglucose both prevented changes to mitochondria and suppressed RCC CD8+ TIL activation and function. These data show that CD28 costimulation can restore RCC CD8+ TIL metabolism and function through rescue of T cell glycolysis that supports mitochondrial mass and activity.

medicine, research & experimental
Targeting Cbl-b in cancer immunotherapy

Ryan C. Augustin,Riyue Bao,Jason J. Luke

DOI: https://doi.org/10.1136/jitc-2022-006007

IF: 12.469

2023-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop resistance. To address this unmet need, efforts across the field are targeting additional coinhibitory receptors, costimulatory proteins, and intracellular mediators that could prevent or bypass anti-PD1 resistance mechanisms. The CD28 costimulatory pathway is necessary for antigen-specific T cell activation, though prior CD28 agonists did not translate successfully to clinic due to toxicity. Casitas B lymphoma-b (Cbl-b) is a downstream, master regulator of both CD28 and CTLA-4 signaling. This E3 ubiquitin ligase regulates both innate and adaptive immune cells, ultimately promoting an immunosuppressive tumor microenvironment (TME) in the absence of CD28 costimulation. Recent advances in pharmaceutical screening and computational biology have enabled the development of novel platforms to target this once ‘undruggable’ protein. These platforms include DNA encoded library screening, allosteric drug targeting, small-interfering RNA inhibition, CRISPR genome editing, and adoptive cell therapy. Both genetic knock-out models and Cbl-b inhibitors have been shown to reverse immunosuppression in the TME, stimulate cytotoxic T cell activity, and promote tumor regression, findings augmented with PD1 blockade in experimental models. In translating Cbl-b inhibitors to clinic, we propose specific gene expression profiles that may identify patient populations most likely to benefit. Overall, novel Cbl-b inhibitors provide antigen-specific immune stimulation and are a promising therapeutic tool in the field of immuno-oncology.

oncology,immunology
Non-canonical PD-1 signaling in cancer and its potential implications in clinic

Haoran Zha,Ying Jiang,Xi Wang,Jin Shang,Ning Wang,Lei Yu,Wei Zhao,Zhihua Li,Juan An,Xiaochun Zhang,Huoming Chen,Bo Zhu,Zhaoxia Li

DOI: https://doi.org/10.1136/jitc-2020-001230

IF: 12.469

2021-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies.

oncology,immunology

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells

[CD28 costimulation and checkpoint inhibition in T cells]

PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

CD28 Costimulation: From Mechanism to Therapy

CD28 co-stimulation: novel insights and applications in cancer immunotherapy

PD-1 suppresses TCR-CD8 cooperativity during T-cell antigen recognition

PD-1 Expression By Dendritic Cells Is a Key Regulator of T-Cell Immunity in Cancer

PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation

CD28/PD1 co-expression: dual impact on CD8+ T cells in peripheral blood and tumor tissue, and its significance in NSCLC patients' survival and ICB response

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis

The Role of the CD28 Family Receptors in T-Cell Immunomodulation

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation

Targeting Cbl-b in cancer immunotherapy

Non-canonical PD-1 signaling in cancer and its potential implications in clinic